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CD4+ Regulatory T cells (Treg) play a critical role in maintaining immune homeostasis.
Various Treg subsets have been identified, however the heterogeneity of Treg
subpopulations during development remains uncharacterized. Using mass cytometry
we obtained single cell data on expression of 35 functional markers to examine the
heterogeneity of Treg cells at birth and in adults. Unsupervised clustering algorithms
FlowSOM and ACCENSE were used to quantify Treg heterogeneity. As expected, Treg in
umbilical cord blood were predominately naïve while Treg in adult blood were
predominately central memory and effector memory cells. Although umbilical cord
blood Treg are mostly naïve cells, we observed multiple phenotypic Treg subsets in
cord blood. Nevertheless, peripheral blood in adults contained higher percentages of Treg
and the heterogeneity of Treg was significantly increased in adults. We also studied Treg
heterogeneity throughout a 2-year period after allogeneic hematopoietic stem cell
transplantation (alloHSCT) and in patients with chronic graft-versus-host disease
(cGVHD). Treg heterogeneity recovered rapidly after alloHSCT and gradually increased
in the first two years post-transplant. However, patients with cGVHD had significantly
fewer distinct Treg subpopulations, proposing a correlation between a disrupted Treg
heterogeneity and cGVHD. Our study is the first to compare human Treg heterogeneity at
birth, in healthy adults and in patients after alloHSCT with and without cGVHD. This
approach to characterize Treg heterogeneity based on expression of a large panel of
functional markers may enable future studies to identify specific Treg defects that
contribute to immune dysfunction.
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- Distinct subpopulations of CD4+ Treg cells are present at birth
and phenotypic Treg heterogeneity increases in adulthood
- CD4+ Treg heterogeneity increases after allogeneic stem cell
transplantation and is reduced during chronic Graft-versus-
Host-DiseaseINTRODUCTION
Regulatory T cells (Tregs) are essential elements of a healthy
immune system. They comprise between 5–10% of the
peripheral blood CD4+ T cell compartment in healthy
individuals and play a critical role protecting their host against
immunopathological damage following inflammatory or
immunological challenges (1, 2). Tregs are able to suppress a
range of effector cell types through several mechanisms, both
direct and indirect, ensuring peripheral tolerance and immune
homeostasis (3, 4). The intricate balance between immune
response and suppression can be disturbed by both a reduced
number of Tregs as well as a decline in their functionality,
potentially leading to autoimmune pathology (5).
Tregs originate in the thymus and can be identified by
expression of CD3, CD4, high levels of surface CD25, low
levels of CD127 and intracellular FoxP3 (6). Tregs can be
further divided into three main maturation categories: naïve,
central memory (CM) and effector memory (EM) (7). Naïve
Tregs express high levels of CD45RA and low levels of CD45R0
and FoxP3, whereas memory Tregs are FoxP3hi and CD45RA- (8,
9). In healthy individuals up to 30% of the regulatory T cells are
naïve (10). As individuals age, the relative fraction of naïve Tregs
decreases due to thymic involution, while the proportion of
memory Tregs increases (11). Nevertheless, recent thymic
emigrants (RTE), which co-express CD31 and CD45RA, are
still present in adults constituting up to 11% of all naive Tregs.
It has been reported that the Treg population in adult
peripheral blood contains up to 22 phenotypically distinct
subpopulations, thus offering new insights into the heterogeneity
of these cells (12). Nevertheless, extensive comparisons between
Treg in adult peripheral blood and umbilical cord blood (CB) have
not previously been undertaken. Presumably, CB Treg are mostly
comprised of a homogeneous population of naïve cells (10, 13, 14).
However, even though the majority of CB Tregs are naïve, CB also
contains small numbers of memory Tregs, possibly due to prenatal
antigen activation (15). It has also been proposed that maternal
cells pass the placenta and remain in fetal lymph nodes, where
these cells induce the development of fetal Tregs that suppress
antimaternal immunity (16). The expansion potential of CB Treg
has been shown to be higher than adult Treg, and expanded CB
Treg are functionally active (17). This has led to the use of
expanded CB Tregs for treatment of GVHD after allo-HSCT
(17). However, the extent to which CB Tregs are a homogenous
population has not been studied or whether the extensive
heterogeneity present in adult Treg is also present in CB Treg.Frontiers in Immunology | www.frontiersin.org 2Mass cytometry by time of flight (CyTOF) allowed us to
investigate CB and adult Treg in unprecedented detail by
simultaneously detecting and quantifying 35 markers in
individual cells (18–20). To quantify heterogeneity and
provide more insight into the phenotype of CB Treg, we used
FlowSOM and ACCENSE for high dimensional analysis of mass
cytometry data. These analytic tools allow us to quantify human
Treg heterogeneity based on expression of a large set of
activation, proliferation, tissue-homing and functional
markers in conjunction with stages of Treg maturation
and differentiation.
These tools revealed heterogeneous populations of Treg in
both CB and adult blood but CB Treg were less heterogeneous
with respect to maturity and functional markers. After allo-
HSCT the number of distinct Treg subpopulations gradually
increased during a two-year follow-up period. Patients with
cGVHD had significantly fewer distinct Treg subpopulations
based on functional markers, proposing a correlation between a
disrupted Treg heterogeneity and cGVHD.METHODS
Donor and Patient Characteristics
Peripheral blood samples were obtained from 14 healthy
individuals (8 males and 6 females) with a median age of 44
years (range, 20–69 years), two children (male of 2 years old and
female of 10 years old) and from five discarded umbilical cord
blood collections (from two males and three females). We also
studied peripheral blood from 10 adult patients who underwent
allogeneic HSCT at the Dana-Farber Cancer Institute and
Brigham and Women’s Hospital, Boston Massachusetts. All
transplant patients received reduced intensity conditioning
with fludarabine plus busulfan followed by infusion of
unmodified G-CSF mobilized peripheral stem cell grafts. No
patients received anti-thymocyte globulin for GVHD prophylaxis
or low-dose interleukin-2 (IL-2) for treatment of chronic GVHD.
Fresh blood samples were obtained at 6 different time points (0, 1, 3,
6, 12, and 24 months) after transplant or during cGVHD (6
months). Patients with relapse were not included. Written
informed consent was obtained from patients and healthy donors
prior to sample collection, in accordance with the Declaration of
Helsinki. Protocol approval was obtained from the Human Subjects
Protection Committee of the Dana-Farber/Harvard Cancer Center.
Sample Preparation
CB mononuclear cells (CBMCs) and PBMCs were isolated from
freshly drawn samples by density gradient centrifugation (Ficoll-
Paque PLUS; GEHealthcare). Freshly isolated CBMCs and PBMCs
from healthy donors were immediately used for antibody staining.
PBMCs from patients were washed and cryopreserved in
BAMBANKER (Lymphotech) before being analyzed.
Metal-Tagged Monoclonal Antibodies
A panel of 35 metal-tagged monoclonal antibodies was used for
analysis of CBMCs and PBMCs. A list of all antibodies andJanuary 2021 | Volume 11 | Article 570550
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All pre-conjugated antibodies were purchased from Fluidigm. All
other antibodies were purchased in carrier-protein-free PBS and
conjugated with the respective metal isotope using the MaxPAR
antibody conjugation kit (Fluidigm) according to the
manufacturer ’s recommended protocol. Metal-labeled
antibodies were diluted to 0.5 mg/ml in Candor PBS Antibody
Stabilization solution (Candor Bioscience GmbH) for long-term
storage at 4°C.
Antibody Staining for Mass Cytometry
CBMCs and PBMCs were washed with MaxPar Cell Staining
Buffer (Fluidigm) and blocked with Human FcR Blocking
Reagent (Miltenyi Biotec) for 10 minutes at room temperature.
Cells were then incubated with all antibodies targeting cell
surface markers for 30 minutes at room temperature and then
washed twice with Cell Staining Buffer. After washing, cells were
fixed with Cytofix Fixation Buffer (BD Biosciences) and
permeabilized with Phosflow Perm Buffer III (BD Biosciences)
following the manufacturer’s instructions. Fixed/permeabilized
cells were washed twice with Cell Staining Buffer and incubated
with all antibodies targeting intracellular antigens for 30 minutes
at room temperature. After staining with intracellular antibodies,
cells were washed twice with Cell Staining Buffer and incubated
with 191/193Ir DNA intercalator (Fluidigm) following theFrontiers in Immunology | www.frontiersin.org 3manufacturer’s instructions. Prior to mass cytometry analysis,
cells were washed twice with Cell Staining Buffer and twice with
MaxPar Water (Fluidigm).
Mass Cytometry
Cells were analyzed on a CyTOF 2 mass cytometer (Fluidigm) at
an event rate of approximately 500 cells/s. To normalize CyTOF
data over different days, EQ Four Element Calibration Beads
(Fluidigm) were added in all samples. Resulting data were
analyzed with software available through Cytobank (www.
cytobank.org). To remove debris and doublets, single cells were
gated based on cell length and DNA content as described by
Bendall et al. (21). To interpret high dimensional single-cell data
produced by mass cytometry, we used a visualization tool based
on the viSNE algorithm that creates a two-dimensional view of
high-dimensional cytometry data at single-cell resolution,
making it possible to not only visually identify interesting and
rare subsets while preserving nonlinearity, but also to gate single-
cell events across different samples (22).
Gating of Populations
Treg were defined by CD25+FOXP3+ co-expression (Figure 1A).
Naive cells were gated from the Treg population with the





FIGURE 1 | Regulatory T cells from cord blood are mostly CD31+ naive cells. (A) Manual gating of Treg based on expression of CD4 and CD25+FOXP3+ co-
expression. (B) Median percentage of Tregs in the CD4+ compartment of cord blood and adult PBMC; the error bars show the range. (C) Representative visual
composition of Treg maturation subsets in viSNE maps showing single cell relationships; subsets are divided by the black line: blue = naïve subset; green = Central
Memory (CM) subset; orange = Effector Memory (EM) subset. (D) Relative composition of Naïve, CM and EM subsets in cord blood and adult Treg. Median values
are shown for five CB and 14 adult Treg samples. (E) Expression of CD31 visualized with viSNE maps within naïve fraction of CB and adult Treg. Cells are colored
according to intensity of CD31 expression. (F) Median percentage of naïve Treg cells expressing CD31+, the error bars show the range. * represents statistical
significance (p-value < 0.05). In ViSNE maps, each point represents a single cell.January 2021 | Volume 11 | Article 570550
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cells were gated by co-expression of CD45RA and CD31 (23).
Each sample was gated manually via Cytobank.
Clustering Analysis
FlowSOM (R package accessible within the www.bioconductor.
org platform) was used for automated clustering. FlowSOM was
run in R Studio and allows for unsupervised clustering and
dimensionality reduction of data obtained from mass cytometry.
Subsequent subpopulation analysis was repeated in ACCENSE
(standalone application accessible from http://www.cellaccense.
com/) for reliability purposes. ACCENSE is a tool for exploratory
analysis of high-dimensional single-cell data such as that
generated by mass cytometry (24). By combining a nonlinear
dimensionality reduction algorithm (t-SNE) with a k-means
clustering algorithm both visualization for exploratory analysis
and automated cell classification into subpopulations is
performed. Subpopulation quantification was completed twice
based on 26 functional markers and 6 maturity markers from the
cytometry panel. ACCENSE was also used to make subsequent
visual figure maps. Supplementary Table 2 shows which
markers were used.
Statistical Analysis
Graphpad Prism 7.04 was used for data analysis. Mann-Whitney
test was used to compare unpaired populations. The Wilcoxon
signed-rank test was used to compare paired samples for
continuous variables and expression levels of proteins between
subpopulations and between different time points. All tests were
2-sided at the significance level of 0.05 and multiple comparisons
were not considered.RESULTS
Prevalence of Treg Maturation Subsets at
Birth and Adulthood
To compare the maturity of the Treg cell compartment between
cord blood and adult blood we gated the single cell data biaxially
in Cytobank to distinguish Tregs in all samples (Figure 1A).
Treg were classified by the co-expression of intracellular FoxP3
and high-expression of surface CD25 (6). For complete
visualization of the gating strategy see Supplementary Figure
1. The median percentage of regulatory T cells in adult blood was
a 4.6-fold higher than cord blood (6.0% vs. 1.3%; Figure 1B) (p <
0.0001). Specific maturation subsets were defined as follows:
naïve (CD45RA+CD62L+), CM (CD45RA-CD62L+), and EM
(CD45RA-CD62L-) (7–9). Figure 1C identifies these three
distinct populations within the Treg compartment and visually
represents the difference between CBMC and adult PBMC. Naïve
Treg cells make up the largest subset in CB at 85.2%, followed by
CM cells at 5.6% and EM at 4.5%. In adult PBMC, CM Treg form
the major subset at 56.5%, followed by EM (25.2%) and naïve
cells (15.2%) (Figure 1D). We also quantified the fraction of
recent thymic emigrants (RTE) within the naïve Treg subset.
RTE can be gated from the naïve population via the expression ofFrontiers in Immunology | www.frontiersin.org 4CD31, seen in Figure 1E. Within CB Treg, a median of 70.7% of
gated CD45RA+ cells expressed CD31. In adult PB Treg, a
median of 10.19% of gated CD45RA+ cells expressed CD31
(p = 0.0002) (Figure 1F).
CD4 Treg Cell Heterogeneity Is
Established in Umbilical Cord
Blood and Increases With Age
We then examined the phenotypic heterogeneity of Treg in CB
and adult peripheral blood by clustering Tregs based on the
expression of 26 functional markers. To quantify heterogeneity
within Treg, we used unsupervised cluster analysis with
FlowSOM. Weber et al, 2016. previously compared 13 flow and
mass cytometry clustering tools, recommending that FlowSOM
(with optimal meta-clustering but without automatic selection of
number of clusters) be used as a first choice for analyzing new
data sets (25). We replicated this analysis with our 26-marker
panel and results were further validated by a separate analysis
tool, ACCENSE. Figure 2A shows Treg cell clustering on
functional markers included in our panel for 4 CB and 4 adult
PB samples. Unsupervised clustering based on all 26 marker
parameters revealed a median of 15.5 distinct clusters in adult
Treg (range, 10–22) and 12 Treg clusters in CB Treg (range, 6–
13) (p = 0.008) (Figure 2B). Although heterogeneity of CB Treg
is substantial this heterogeneity increases significantly in adults.
There was no variation of number of clusters within healthy
controls regarding their age. In fact, we analyzed Treg
heterogeneity in two children (2 and 10 years old), and both
had 16 and 18 clusters, respectively (Supplementary Figure 2).
This finding suggests that Treg heterogeneity is acquired very
early in life.
CD4 Treg Cell Maturation Heterogeneity
Also Increases Between Birth and
Adulthood
After establishing that heterogeneity of Treg in umbilical cord
blood increases in adulthood, we further analyzed phenotypic
heterogeneity related to levels of Treg maturity within naïve, CM
and EM Treg subpopulations. Figures 3A, B show the gating
strategy using CD45RA and CD62L to identify the naïve/CM/
EM subsets in a viSNE map. This allowed us to visualize and
quantify the following phenotypic and functional markers in
each subset: CD31 (recent thymic emigrant marker), Ki-67
(marker for proliferation), CD95 (marker of extrinsic pathway
apoptosis), and HLA-DR (activation marker) (Figures 3C, D).
The percentage of CD31+ Tregs within the naïve subset of CB
was significantly higher than in naïve adult Tregs (p = 0.0002).
These results are consistent with the previously established
higher expression of CD31 in CB cells compared to adult
Tregs. In contrast, all 3 maturation subsets of adult Tregs
express significantly more CD95 than corresponding CB Treg
subpopulations. Although few naïve Tregs express CD95, the
expression of this marker was also significantly different (p =
0.01) between CB an adult Treg. Larger differences were seen
when comparing CD95 expression in CM and EM Treg
populations in CB and adults (p = 0.005 and 0.0002,January 2021 | Volume 11 | Article 570550
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susceptible to apoptosis in adult than in CB Tregs. With regard
to the activation marker HLA-DR, naïve CB Tregs expressed
higher levels of HLA-DR than naïve adult Tregs (p = 0.0002).
This suggests that naïve Tregs are the most activated subset
within CB. There was little difference in expression of HLA-DR
in CM and EM Tregs of newborns and adults, perhaps indicating
that these subsets have similar activity in both age groups. Ki-67
is expressed at higher levels in all CB Treg subsets, indicating that
all CB Treg cells proliferate at a higher rate than their adult
counterparts. For each of the subgroups, significant differences
were found, with p = 0.0003 for naïve, p = 0.0002 for CM and p =
0.0002 for EM Tregs.
Differential Expression of Markers in
Distinct Populations Reveal Functional
Characteristics
Even though our method of unsupervised clustering did not
allow us to directly compare expression of markers in different
metaclusters, we analyzed the expression of all functional
markers in CB versus adult PBMC. From the 26 functional
markers (Supplementary Figure 3), eight showed significantly
different levels of expression between umbilical cord blood and
adult peripheral blood. CB Treg cells expressed higher levels of
Ki-67 (p = 0.0093) (a nuclear proliferation marker), PD-1 (p =
0.0485) (a marker for reduced apoptosis and exhaustion),
CCR9 (p = 0.0196) (a chemokine receptor that regulates
lymphocyte trafficking to the small intestine), and CCR7 (p =
0.0036) (a chemokine receptor that regulates lymphocyte
trafficking to lymph nodes). On the other hand, adults
showed higher expression levels of CCR4 (p = 0.0196) (a
chemokine receptor that regulates lymphocyte trafficking to
skin), CCR5 (p = 0.0021) and CXCR3 (p = 0.0010) (chemokine
receptors that regulates lymphocyte trafficking to inflamed
tissues), and CD95 (p = 0.0273) (a marker of extrinsic
pathway apoptosis) (Figure 4).
Other functional marker differences between CB and adult
PBMC that were of interest included CTLA-4 (p = 0.0624), CLAFrontiers in Immunology | www.frontiersin.org 5(p = 0.0800), Tbet (p = 0.0800), ICOS (p = 0.0800), and PDL-1
(p = 0.0800), which were slightly lower in adult Tregs.Treg Cell Heterogeneity Increases After
Allogeneic Hematopoietic Stem Cell
Transplantation
Acknowledging the important role of regulatory T cells in
allogeneic hematopoietic stem cell transplantation (alloHSCT)
and following our previous studies describing the reconstitution
of Treg after alloHSCT (23), we examined the heterogeneity of
Treg subsets at various times after alloHSCT. Using the same
mass cytometry panel, we analyzed Tregs from five patients that
received unmodified peripheral blood stem cell grafts at 6 time
points: Day 0 and days 1, 3, 6, 12, and 24 months after transplant.
None of these patients developed acute or chronic GVHD during
this time period. The percentage of CD4+ Treg cells increased
gradually in the first 6 months after alloHSCT and subsequently
remained relative stable throughout the 2-year follow up period
(Figure 5A).
We subsequently examined Treg heterogeneity during this
period (Figures 5B, C). Compared to Treg pre transplant, there
was a decrease in the number of Treg subsets 1 month after
transplant. We then observed an increase from a median of 9.5
subpopulations to 14 subpopulations 3 months after transplant.
This level of Treg heterogeneity remained relatively stable from 3
to 24 months after transplant in this group of patients who did not
develop acute or chronic GVHD. Interestingly, only a fewmarkers
vary their expression noticeably since the transplant. D49a, GITR,
CTLA-4, CXCR3, Tim-3, CCR7, CD28, and CCR4 are 2-fold
more expressed at day 0 compared to after month 1. From month
3 onwards the expression of the markers remains constant among
alloHSCT patients and similar to adult Treg cells.
Treg Cell Heterogeneity is Reduced During
cGVHD
Previous studies have shown that patients with active chronic
GVHD have a lower frequency of Treg cells (22, 26). ToA B
FIGURE 2 | Analysis of Treg heterogeneity by unsupervised clustering based on expression of 26 functional markers. (A) Treg metaclusters identified by ACCENSE in
four representative samples of cord blood (CB) and four adult Treg samples. Each point represents one cell, the color of the cells denotes a specific cluster. The number
of metaclusters identified in each sample is shown below each box. (B) Phenotypic heterogeneity of Treg in CB and adult PB. Five CB and 14 adult PB samples were
studied. The center bar in the box is the median; Whiskers illustrate the minimum and maximum values obtained. * represents statistical significance (p < 0.05).January 2021 | Volume 11 | Article 570550
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associated with abnormal Treg heterogeneity we examined
peripheral blood from five patients with chronic GVHD and
compared results to samples obtained 6 months after alloHSCT
from five patients without GVHD that had been previously
analyzed. Gating on CD4+FoxP3+ Treg, we first compared
Treg percentages in patients with and without cGVHD.
Median %Treg was 4.28 (range, 2.03–6.77) in patients withFrontiers in Immunology | www.frontiersin.org 6cGVHD compared to 7.74 (range, 4.18–9.27) in patients
without cGVHD (p = 0.055). Using FlowSOM, we compared
Treg heterogeneity in samples from patients with and without
cGVHD. Treg from patients with cGVHD were found to have 11
Treg metaclusters (range, 10–13) compared to 14 metaclusters
(range, 12–21) in patients without cGVHD (p = 0.02) (Figures
5D, E). Although our method of unsupervised clustering did not
identify specific characteristics of missing metaclusters inA B
DC
FIGURE 3 | Treg maturation in cord blood and adult peripheral blood. (A) Expression of CD45RA and CD62L in cord blood and adult Treg. Color indicates the level
of expression of the labeled marker in viSNE maps from two representative samples. (B) Visual representation of Treg maturation in viSNE maps based on
expression of CD45RA and CD62L. Subsets are divided by the black line: blue = naïve Treg; green = Central Memory (CM) Treg; orange = Effector Memory (EM)
Treg. (C) Expression of specific functional markers in representative examples of cord blood and adult Treg. (D) Median percentage of marker positive cells within
naïve, CM and EM Treg subsets. Results are compared for five cord blood Treg samples and 14 adult Treg samples. * represents statistical significance (*p < 0.05,
**p < 0.005, ***p < 0.0005). In viSNE maps, each point represents a single cell. Cells are colored according to intensity of expression of the indicated marker
(excluding B).January 2021 | Volume 11 | Article 570550
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significant difference in expression of Helios and CLA between
people with and without cGVHD (Supplementary Figure 4).Frontiers in Immunology | www.frontiersin.org 7Helios was expressed at higher levels in patients without cGVHD
while the expression of CLA was higher in cGVHD patients. PD-
1, CCR4 and HLA-DR also were highly expressed (non-A B
FIGURE 4 | Cord blood and adult peripheral T regulatory cells differ in expression of various markers. (A) viSNE maps show the expression of functional Treg
markers in cord blood and adult PBMC, color indicates the level of expression of the labeled marker. (B) Bar graphs matching the viSNE representation to their left
showing median expression intensity for each marker, the error bars show the IQ range. * represents statistical significance (p < 0.05). In ViSNE maps, each point
represents a single cell. Cells are colored according to intensity of expression of the indicated marker.January 2021 | Volume 11 | Article 570550
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BCL-2, and CD39 the opposite was observed, with a non-
significant but higher expression in cGVHD patients.DISCUSSION
Using mass cytometry and advanced computational algorithms
to simultaneously measure expression of 35 phenotypic and
functional markers in individual cells, we undertook a detailed
analysis of Treg heterogeneity in humans. Our study initially
focused on Treg in umbilical cord blood and peripheral blood in
healthy adults and subsequently was expanded to include Tregs
reconstituting after allogeneic HSCT and in patients with
cGVHD. Unsupervised clustering algorithms based on 26
functional markers were used to establish the number of Treg
metaclusters in individual samples and thereby quantify
heterogeneity within the Treg population in each sample at
each time point. This resulted in a unique examination of Treg
heterogeneity throughout life and through a critical period where
Treg are known to play an important role in immune
reconstitution and the establishment of immune tolerance.
At birth, CB Tregs are predominately comprised of naïve cells
(13, 14). Genomic diversity and proliferative capacity of CB Treg
is very high (17), and this has facilitated the use of CB-derived in
vitro expanded Treg for treatment or prevention of GVHD after
alloHSCT (27). Our studies confirmed that CB Treg are
predominately naïve cells, with a high fraction of recent thymic
emigrants. In contrast, adult Treg are more mature, being
predominately CM and EM cells with a much smaller fractions
of naïve cells and recent thymic emigrants. Nevertheless, CB Treg
were found to be relatively heterogeneous reflecting variable statesFrontiers in Immunology | www.frontiersin.org 8of differentiation, maturation and activation, despite being
predominately naïve cells. Treg heterogeneity increased
significantly in healthy adults reflecting past exposures and
additional levels of differentiation, maturation and activation
in vivo.
To assess heterogeneity within defined stages of Treg
maturation we compared the expression of CD31 (recent
thymus emigrant), Ki-67 (proliferation), CD95 (apoptosis), and
HLA-DR (functional activation) in naïve, CM, and EM Treg. The
frequency of CD31+ Tregs in the naïve CB Treg was significantly
higher than in naïve adult Treg. This likely reflects decreased
thymic function and increased homeostatic expansion of naïve T
cells in adults. We also observed increased expression of CD95 in
naïve, CM and EM subpopulations in adult Tregs compared to
CB Treg. This likely reflects higher levels of exhaustion and
terminal differentiation in adult Treg. In contrast, HLA-DR was
more highly expressed naïve CB Treg and Ki-67 was more highly
expressed at all levels of differentiation in CB Treg, indicating
that all subsets of CB Treg are activated and highly proliferative.
In patients who undergo alloHSCT, recipient T cells are
rapidly replaced as donor cells engraft and reconstitute a fully
functional immune system in the recipient. Proper functioning
of the donor immune system requires balanced recovery of
regulatory elements as well as effector cells and the development
of cGVHD can be predicted by impaired recovery of Treg leading to
an abnormally low ratio of Treg to conventional effector T cells
(28). Enhancement of Treg recovery through Treg infusions or
administration of low dose IL-2 to selectively induce expansion of
Treg in vivo can prevent or treat cGVHD progression (27, 29–33).
The ability to manipulate Treg after alloHSCT and in patients with
autoimmune diseases has sparked interest in the development of
Treg-directed therapies. However, there has been relatively littleA B D
EC
FIGURE 5 | Regulatory T cell heterogeneity after alloHSCT and during cGVHD. (A) The median Treg percentage within the CD4+ compartment in healthy donors,
before and after alloHSCT and in patients with chronic GVHD 6 months after alloHSCT. Error bars show the range of values. (B) Treg metaclusters after alloHSCT
identified by ACCENSE, based on expression of 26 functional markers. Each point represents one cell and colors denote individual clusters. Results shown are for a
representative patient and the number of metaclusers at each time point is shown below each figure. (C) The number of Treg metaclusters identified before and after
alloHSCT. Results shown are median values for five patients without acute or chronic GVHD after transplant. Error bars show range for values for each time point.
(D) Treg metaclusters in a representative patient with chronic GVHD 6 months after alloHSCT. Colors denote individual clusters identified by ACCENSE. (E) Treg
heterogeneity in patients with and without chronic GVHD 6 months after alloHSCT. Box and whisker plots show the number of Treg metaclusters based on
expression of 26 functional markers. The center bar in the box is the median. Whiskers illustrate the minimum and maximum values.January 2021 | Volume 11 | Article 570550
Matos et al. Maturation and Heterogeneity of Tregsconsideration of the potential importance of functional Treg
heterogeneity in addition to the ability to simply increase Treg
counts in vivo. In our analysis of Treg heterogeneity in adult patients
after transplant we found that Treg heterogeneity recovered rapidly
in patients without acute or chronic GVHD. By 3–6 months after
alloHSCT, levels of Treg heterogeneity were similar to healthy
adults. However, the number of Treg metaclusters in patients
with cGVHD at 6 months was significantly decreased compared
to patients without cGVHD. These findings suggest that lack of
functional Treg subsets may contribute to the development of
cGVHD in addition to a simple numerical deficiency in this
setting. High T cell receptor (TCR) diversity has been correlated
with establishment and maintenance of self-tolerance (34) and
required for optimal suppressive function of Treg cells in murine
models of GVHD (35). Hence, future studies should correlate the
TCR repertoire diversity to Treg subpopulations in order to
determine whether subpopulations share a clonal origin.
In summary, our findings reveal considerable heterogeneity of
Treg subsets that is not detected in routine characterization of Treg
by flow cytometry with a limited set of markers. We also show that
Treg heterogeneity varies considerably among individuals and in
patients after alloHSCT. Although this heterogeneity is based on the
variable expression of functional markers, further studies are needed
to establish the extent to which this phenotypic heterogeneity
reflects actual functional differences between different Treg
metaclusters and the ability of different Treg metaclusters to
regulate different immune cells and immune networks in vivo.
The main limitation of our study was the inability to define each
individual cluster and compare them between samples. Since Treg
are known to be capable of functional plasticity it will also be
important to examine the stability of distinct metaclusters in vitro
and in vivo. As Treg directed therapies are evaluated in patients with
autoimmune diseases as well as GVHD, it may be important to
examine the effects of these interventions on Treg heterogeneity as
well as the number of circulating Treg.DATA AVAILABILITY STATEMENT
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based on all 26 functional markers. Treg subpopulation clusters made with
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old) peripheral blood samples. Each point represents one cell, the color of the cells
denotes a specific cluster.
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cord blood and adult PBMC. (A) Heatmaps with marker expression from low (black)
to high (yellow). (B) Bar graphs showing the median intensity range. * represents
statistical significance (p-value < 0.05).
SUPPLEMENTARY FIGURE 4 | Functional marker discrepancies between
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